

RECEIVED

JUL 20 2001

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

TECH CENTER 1600/2900

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/445,865
		Filing Date	February 11, 2000
		First Named Inventor	Philip John Burke
		Group Art Unit	1643
		Examiner Name	
Sheet 2 of 9	Attorney Docket Number	ERD 100	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
GN		EP	0 251 744	A2	Delta Biotechnology Ltd.	01-07-1988		
		EP	0 258 067	A2	Delta Biotechnology Ltd.	03-02-1988		
		EP	0 302 473	A2	Bristol-Myers Co.	02-08-1989		
		EP	0 415 731	A2	The Wellcome Foundation Ltd.	03-06-1991		
		WO	88/07378	A1	Cancer Research Campaign Technology Ltd.	10-06-1988		
		WO	89/10140	A1	Cancer Research Campaign Technology Ltd.	11-02-1989		
		WO	90/01063	A1	Delta Biotechnology Ltd.	02-08-1990		
		WO	91/09867	A1	Imperial Cancer Research Technology Ltd.	07-11-1991		
GN		WO	91/11201	A1	Imperial Cancer Research Technology Ltd.	08-07-1991		
		WO	93/08288	A1	Cancer Research Campaign Technology Ltd.	04-29-1993		
		WO	93/13805	A1	Bagshawe	07-22-1993		
		WO	93/13806	A1	Bagshawe	07-22-1993		
GN		WO	95/12678	A1	Cancer Research Campaign Technology Ltd.	05-11-1995		
		WO	97/07097	A1	Auckland Division Cancer Society of New Zealand	02-27-1997		
		WO	97/24143	A1	AEPACT, Ltd.	07-10-1997		
		WO	97/20580	A1	AEPACT, Ltd.	06-12-1997		
GN		WO	97/24143	A1	AEPACT, Ltd.	07-10-1997		
		WO	98/22577	A1	Masucci	05-28-1998		
GN		WO	98/24478	A2	AEPACT, Ltd.	06-11-1998		

Examine Signature

Date Considered

11/20/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

RECEIVED

JUL 20 2001

Please type a plus sign (+) inside this box →



TECH CENTER 1600/2000

PTO/SB/08A (10-96)
Applicable through 10/31/99. OMB 0651-0031
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Fill in as many sheets as necessary)		Application Number	09/445,865
		Filing Date	February 11, 2000
		First Named Inventor	Philip John Burke
		Group Art Unit	1643
		Examiner Name	
		Attorney Docket Number	ERD 100
Sheet 1	of 9		

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
CW		ANLEZARK, et al., "The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from <i>Escherichia coli</i> --a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT)," <i>Biochem. Pharmacol.</i> 1992 44(12):2289-95.	
		BETTER, et al., "Escherichia coli secretion of an active chimeric antibody fragment," <i>Science</i> 240(4855):1041-43 (1988).	
		BIRD, et al., "Single-chain antigen-binding proteins," <i>Science</i> 242(4877):423-26 (1988).	
		BISCHOFF, et al., "An adenovirus mutant that replicates selectively in p53-deficient human tumor cells," <i>Science</i> 274(5286):373-76 (1996).	
		BOLAND, et al., "The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide)," <i>Biochem. Pharmacol.</i> 41(6-7):867-75 (1991).	
		BRADL, et al., "Malignant melanoma in transgenic mice," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 88(1):164-68 (1991).	
		BRAWER, "Prostate specific antigen. A review," <i>Acta. Oncol.</i> 30(2):161-68 (1991).	
		CHEN, et al., "Expression of rat liver NAD(P)H:quinone-acceptor oxidoreductase in <i>Escherichia coli</i> and mutagenesis in vitro at Arg-177," <i>Biochem. J.</i> 284 (Pt 3):855-60 (1992).	
		CHEN, et al., "Molecular basis of the catalytic differences among DT-diaphorase of human, rat, and mouse," <i>J. Biol. Chem.</i> 272(3):1437-39 (1997).	
		CLARK, et al., "Role of the Bp35 cell surface polypeptide in human B-cell activation," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 82(6):1766-70 (1985).	

Examiner's Signature	<i>Gar Burke</i>	Date Considered	11/20/02
----------------------	------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

JUL 20 2001

TECH CENTER 1600/2900

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

JUL 16 2001

PATENT & TRADEMARK OFFICE

Complete if Known

Application Number

09/445,865

Filing Date

February 11, 2000

First Named Inventor

Philip John Burke

Group Art Unit

1643

Examiner Name

Attorney Docket Number

ERD 100

Sheet 4 of 9

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
bw		CONNORS & WISSON, "Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity," <i>Nature</i> 210(38):866-67 (1966).	
		CORVALAN & SMITH, "Construction and characterisation of a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids," <i>Cancer Immunol. Immunother.</i> 24(2):127-32 (1987).	
		CORVALAN, et al., "Increased therapeutic effect of vinca alkaloids targeted to tumour by a hybrid-hybrid monoclonal antibody," <i>Cancer Immunol. Immunother.</i> 24(2):138-43 (1987).	
		CORVALAN, et al., "Specific in vitro and in vivo drug localisation to tumour cells using a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids," <i>Cancer Immunol. Immunother.</i> 24(2):133-37 (1987).	
		COTTEN, et al., "High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 89(13):6094-98 (1992).	
		COUSSENS, et al., "Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene," <i>Science</i> 230(4730):1132-39 (1985).	
		CULVER, et al., "In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors," <i>Science</i> 256(5063):1550-52 (1992).	
		CURIEL, "Adenovirus facilitation of molecular conjugate-mediated gene transfer," <i>Prog. Med. Virol.</i> 40:1-18 (1993).	
bw		DRABEK, et al., "The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954," <i>Gene Ther.</i> 4(2):93-100 (1997).	
bw		FRIEDLOS & KNOX, "Metabolism of NAD(P)H by blood components. Relevance to bioreductively activated prodrugs in a targeted enzyme therapy system," <i>Biochem. Pharmacol.</i> 44(4):631-35 (1992).	

Examiner's Signature

Date Considered

4/20/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

JUL 20 2001

TECH CENTER 1600/2900

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/445,865
		Filing Date	February 11, 2000
		First Named Inventor	Philip John Burke
		Group Art Unit	1643
		Examiner Name	
Sheet 5 of 9		Attorney Docket Number	ERD 100

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
GW		FRIEDLOS, et al., "Identification of novel reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2)," <i>Biochem. Pharmacol.</i> 44(1):25-31 (1992).	
		FRIEDLOS, et al., "Potentiation of CB 1954 cytotoxicity by reduced pyridine nucleotides in human tumour cells by stimulation of DT diaphorase activity," <i>Biochem. Pharmacol.</i> 44(9):1739-43 (1992).	
		GILLILAND, et al., "Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 85(20):7719-23 (1988).	
		GREEN, et al., "Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene," <i>Cancer Gene Ther.</i> 4(4):229-38 (1997).	
		HARWOOD, et al., "Comparative tumour localization of antibody fragments and intact IgG in nude mice bearing a CEA-producing human colon tumour xenograft," <i>Eur. J. Cancer Clin. Oncol.</i> 21(12):1515-22 (1985).	
		HELLSTRÖM, et al., "Monoclonal mouse antibodies raised against human lung carcinoma," <i>Cancer Res.</i> 46(8):3917-23 (1986).	
		HURRELL, "Monoclonal Hybridoma Antibodies: Techniques and Applications," (CRC Press).	
		HUSTON, et al., "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 85(16):5879-83 (1988).	
		JACKSON, et al., "The tyrosinase-related protein-1 gene has a structure and promoter sequence very different from tyrosinase," <i>Nucleic Acids Res.</i> 19(14):3799-804 (1991).	
		JAISWAL, "Human NAD(P)H:quinone oxidoreductase2. Gene structure, activity, and tissue-specific expression," <i>J. Biol. Chem.</i> 269(20):14502-08 (1994).	

Examiner's
Signature

Date Considered

4/20/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

JUL 20 2001

Please type a plus sign (+) inside this box →


 PTO/SB/08A (10-96)
 Approved for use by the Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
 TECH CENTER 1000/2000

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/APTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) JUL 16 2001 PATENT & TRADEMARK OFFICE		Application Number	09/445,865
		Filing Date	February 11, 2000
		First Named Inventor	Philip John Burke
		Group Art Unit	1643
		Examiner Name	
Sheet 6	9	Attorney Docket Number	ERD 100

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
GW		JAISWAL, "Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6," <i>Biochemistry</i> . 29(7):1899-906 (1990).	
		KHAN & ROSS, "Tumour-growth inhibitory nitrophenylaziridines and related compounds: structure-activity relationships," <i>Chem. Biol. Interact.</i> 1(1):27-47 (1969).	
		KNOX, et al., "The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase," <i>Biochem. Pharmacol.</i> 44(12):2297-301 (1992).	
		KNOX, et al., "The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)," <i>Cancer Metastasis Rev.</i> 12(2):195-212 (1993).	
		KNOX, et al., "Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT)," <i>Biochem. Pharmacol.</i> 49(11):1641-47 (1995).	
		KURIYAMA, et al., "A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector," <i>Cell Struct. Funct.</i> 16(6):503-10 (1991).	
		LEDLEY, "Nonviral gene therapy: the promise of genes as pharmaceutical products," <i>Hum. Gene Ther.</i> 6(9):1129-44 (1995).	
		LIAO & WILLIAMS-ASHMAN, "Enzymatic oxidation of some non-phosphorylated derivatives of dihydronicotinamide," <i>Biochem. and Biophys. Res. Comm.</i> 4:208-13 (1961).	
		LIAO & WILLIAMS-ASHMAN, "Inhibition of the enzymic oxidation of some dihydropyridines by polycyclic aromatic hydrocarbons," <i>Biochem. Pharmacol.</i> 6:53-54 (1961).	
		LIAO, et al., "Purification and properties of a flavoprotein catalyzing the oxidation of reduced ribosyl nicotinamide," <i>J. Biol. Chem.</i> 237:2981-87 (1962).	

Examiner's Signature	<i>Gar R. Smith</i>	Date Considered	11/20/02
----------------------	---------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

JUL 20 2001


Please type a plus sign (+) inside this box →


 TECH CENTER 1600/2900
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/445,865
		Filing Date	February 11, 2000
		First Named Inventor	Philip John Burke
		Group Art Unit	1643
		Examiner Name	
		Attorney Docket Number	ERD 100
Sheet	7 of 9		

OTHER ART - NON PATENT LITERATURE DOCUMENTS

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		LUNDWALL, "Characterization of the gene for prostate-specific antigen, a human glandular kallikrein," <i>Biochem. Biophys. Res. Commun.</i> 161(3):1151-9 (1989).	
		MARTIN & PAPAHAJOPOULOS, et al., "Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting," <i>J. Biol. Chem.</i> 257(1):286-8 (1982).	
		MAUGER, et al., "Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme," <i>J. Med. Chem.</i> 37(21):3452-58 (1994).	
		MICHAEL, et al., "Addition of a short peptide ligand to the adenovirus fiber protein," <i>Gene Ther.</i> 2(9):660-68 (1995).	
		MILLER & VILE, "Targeted vectors for gene therapy," <i>FASEB J.</i> 9(2):190-99 (1995).	
		MORRISON, et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 81(21):6851-55 (1984).	
		NASSANDER, et al., "In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice," <i>Cancer Res.</i> 52(3):646-53 (1992).	
		NEUBERGER, et al., "Recombinant antibodies possessing novel effector functions," <i>Nature</i> 312(5995):604-08 (1984).	
		O'SULLIVAN, et al., "Comparison of two methods of preparing enzyme-antibody conjugates: application of these conjugates for enzyme immunoassay," <i>Anal. Biochem.</i> 100(1):100-08 (1979).	
	RIEGMAN, et al., "Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene," <i>Biochem. Biophys. Res. Commun.</i> 159(1):95-102 (1989).		

Examiner's Signature	<i>Gar B. Miller</i>	Date Considered	11/20/02
----------------------	----------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

JUL 20 2001

TECH CENTER 1600/2900

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/445,865
		Filing Date	February 11, 2000
		First Named Inventor	Philip John Burke
		Group Art Unit	1643
		Examiner Name	
		Attorney Docket Number	ERD 100
Sheet	8	9	

OTHER ART - NON PATENT LITERATURE DOCUMENTS

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
GW		SAIKI, et al., "Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase," <i>Science</i> 239(4839):487-91 (1988).	
		SAMBROOK, et al., <u>Molecular Cloning: A Laboratory Manual</u> Cold Spring Harbor Laboratory Press, Cold Spring Harbor: New York (1989).	
		SCHREWE, et al., "Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression," <i>Mol. Cell. Biol.</i> 10(6):2738-48 (1990).	
		SHARMA, et al., "Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model," <i>Br. J. Cancer.</i> 61(5):659-62 (1990).	
		SHERWOOD, "Advanced drug delivery reviews: enzyme prodrug therapy," <i>Adv. Drug Del. Rev.</i> 22:269-88 (1996).	
		SKERRA, et al., "Assembly of a functional immunoglobulin Fv fragment in <i>Escherichia coli</i> ," <i>Science</i> 240(4855):1038-41 (1988).	
		TROWELL, "The cytotoxic action of mitotic poisons on lymphocytes <i>in vitro</i> ," <i>Biochemical Pharmacology</i> 5:53-63 (1960).	
		WAGNER, et al., "Transferrin-polycation conjugates as carriers for DNA uptake into cells," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 87(9):3410-14 (1990).	
		WARD, et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> 341(6242):544-46 (1989).	
		WHISSON & CONNORS, "Cure of mice bearing advanced plasma cell tumours with aniline mustard," <i>Nature</i> 206(985):689-91 (1965).	

Examiner's Signature		Date Considered	11/20/02
----------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) 		Complete if Known	
		Application Number	09/445,865
Sheet	9	Filing Date	February 11, 2000
		First Named Inventor	Philip John Burke
		Group Art Unit	1643
		Examiner Name	
		Attorney Docket Number	ERD 100

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
W		WINTER & MILSTEIN, "Man-made antibodies," <i>Nature</i> 349(6307):293-99 (1991).	
W		WU, et al., "Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase," <i>Arch. Biochem. Biophys.</i> 347(2):221-28 (1997).	
W		ZOLA, "Monoclonal Antibodies: A manual of techniques," (CRC Press, 1988).	

Examiner's Signature		Date Considered	11/20/02
----------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.